Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.
Follow-Up Questions
Odonate Inc 的 CEO 是谁？
Mr. Kevin Tang 是 Odonate Inc 的 Chairman of the Board，自 2013 加入公司。
ODTC 股票的价格表现如何？
ODTC 的当前价格为 $0，在上个交易日 decreased 了 0%。
Odonate Inc 的主要业务主题或行业是什么？
Odonate Inc 属于 Pharmaceuticals 行业，该板块是 Health Care
